BiomX Inc.

BiomX Inc. (ticker: PHGE) is a clinical-stage biopharmaceutical company focused on developing phage-based therapies targeting bacterial infections associated with chronic diseases. The company became publicly traded in 2019 following a SPAC merger with Chardan NexTech Acquisition Corp, a blank-check vehicle sponsored by Chardan NexTech LLC and affiliated with Chardan Capital Markets. BiomX operates in the biotechnology sector, with its pipeline concentrated on phage therapy candidates for conditions including chronic rhinosinusitis and atopic dermatitis. The company filed an 8-K with the SEC on July 9, 2024, under accession number 0001213900-24-060128, disclosing a reportable event to investors. For complete filing history, pipeline updates, and institutional data on BiomX and hundreds of other SPAC-origin companies, sign up for full access at SpacDesk.